AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 242 min read$NAMS

Kooij Louise Frederika sold $1.2M of NAMS

Kooij Louise Frederika (Chief Accounting Officer) sold 40,000 shares of NewAmsterdam Pharma Co N.V. (NAMS) at an average of $30.20 ($30.20–$30.73, $1.21M total) across 2 trades on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kooij Louise Frederika
Published Jun 24, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:49 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NAMS
Neutral
medium confidence
Mentioned
$NAMS
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NAMSNeutralLow
01

Why it matters

The CFO’s open-market sale under a 10b5-1 plan is disclosed, but the text contains no new company performance, clinical, regulatory, or deal information.

02

Market read

Traders may note the insider sale for sentiment, but it is unlikely to change valuation absent other catalysts.

03

What to watch

The filing does not state tax, diversification, or other personal drivers; without follow-on buys or changes in trading patterns, signal quality remains low.

Relevance 5/10Novelty 3/10Timing: filed 2026-06-24, transaction dated 2026-06-22

Background

The article is an SEC Form 4 insider transaction disclosure for NewAmsterdam Pharma (NAMS).

Company-level read

Ticker impact

$NAMSNeutralMedium confidence
Context

NewAmsterdam Pharma insider Form 4 shows CFO Kooij Louise Frederika sold about 40,000 shares for roughly $1.21M under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a disclosed open-market sale with a pre-arranged 10b5-1 plan, and the article provides no accompanying operational or guidance change.

Market effects

Sector

Minimal; this is company-specific insider trading with no sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it is a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish expectations, so traders may ignore it.

Key entities

  • issuer
    NewAmsterdam Pharma Co N.V.

    Subject of the Form 4 insider sale disclosure.

  • insider
    Kooij Louise Frederika

    Chief Accounting Officer who sold shares.

Read at source← All news

Related articles

AUG 5
$NAMSMed

NewAmsterdam Pharma Co N.V. (NAMS): Results of Operations and Financial Condition

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nams-ex99_1.htm EX-99.1 EX-99.1 NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results – Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis plann

SEC EDGAR 8-K7 min
JUL 24
$NAMSMed

NewAmsterdam, Menarini Cholesterol Drugs Receive Positive Opinion From CHMP

NewAmsterdam Pharma (NAMS) and Menarini said the EMA CHMP issued a positive opinion for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for adults with primary hypercholesterolemia. CHMP based on Phase 3 BROADWAY, BROOKLYN and TANDEM; LDL-C fell up to 40% with monotherapy and about 50% with the combo vs placebo. European Commission decision expected H2 2026.

rttnews.com3 min
JUL 24
$NAMSMedAI 8/10

Menarini Industrie Farmaceutiche Riunite: NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Ob

NewAmsterdam Pharma (Nasdaq: NAMS) and Menarini said the EMA CHMP issued a positive opinion recommending EU marketing authorization for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for primary hypercholesterolemia. The recommendation is based on Phase 3 BROADWAY, BROOKLYN, and TANDEM data showing LDL-C reductions up to 40% and about 50%. The European Commission decision is expected in 2H26.

finanznachrichten.de6 min
JUL 24
$NAMSMedAI 8/10

NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapi

NewAmsterdam Pharma (Nasdaq: NAMS) and Menarini said the EMA CHMP issued a positive opinion recommending marketing authorization in Europe for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for primary hypercholesterolemia. The recommendation is based on Phase 3 BROADWAY, BROOKLYN, and TANDEM results showing LDL-C reductions up to 40% and about 50%. European Commission decision expected in 2H26.

finanznachrichten.de4 min